CA2958085A1 - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents

Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition Download PDF

Info

Publication number
CA2958085A1
CA2958085A1 CA2958085A CA2958085A CA2958085A1 CA 2958085 A1 CA2958085 A1 CA 2958085A1 CA 2958085 A CA2958085 A CA 2958085A CA 2958085 A CA2958085 A CA 2958085A CA 2958085 A1 CA2958085 A1 CA 2958085A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
kinase
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2958085A
Other languages
English (en)
French (fr)
Inventor
Cynthia Lander
Colleen Brophy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CA2958085A1 publication Critical patent/CA2958085A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
CA2958085A 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition Abandoned CA2958085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/473,339 2014-08-29
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
CA2958085A1 true CA2958085A1 (en) 2016-03-03

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2958085A Abandoned CA2958085A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Country Status (12)

Country Link
US (2) US9890200B2 (enExample)
EP (1) EP3185883A4 (enExample)
JP (1) JP2017528454A (enExample)
KR (1) KR20170044171A (enExample)
CN (1) CN107073075A (enExample)
AU (1) AU2015308761A1 (enExample)
BR (1) BR112017003731A2 (enExample)
CA (1) CA2958085A1 (enExample)
MX (1) MX2017002476A (enExample)
RU (1) RU2017110093A (enExample)
SG (1) SG11201701135WA (enExample)
WO (1) WO2016033432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
JP2018512401A (ja) * 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
CN112920256B (zh) * 2019-11-21 2022-08-19 上海医药工业研究院 一种治疗哮喘的生物肽及其应用
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
EP0745063B1 (en) * 1994-02-17 1999-03-24 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DE60026982T2 (de) 1999-04-05 2006-11-16 Mannkind Corp., Danbury Verfahren zur bildung von feinem pulver
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (enExample) 2006-02-22 2015-07-10 Mannkind Corp
EP2010153A2 (en) * 2006-04-03 2009-01-07 Teva Pharmaceutical Industries Limited Drug microparticles
AU2007342674B2 (en) 2007-01-10 2013-09-19 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008098096A1 (en) 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
US9890200B2 (en) 2018-02-13
WO2016033432A9 (en) 2016-04-21
CN107073075A (zh) 2017-08-18
US20180194817A1 (en) 2018-07-12
WO2016033432A1 (en) 2016-03-03
BR112017003731A2 (pt) 2017-12-05
RU2017110093A3 (enExample) 2018-10-01
KR20170044171A (ko) 2017-04-24
JP2017528454A (ja) 2017-09-28
US20150064134A1 (en) 2015-03-05
AU2015308761A1 (en) 2017-02-23
US10562947B2 (en) 2020-02-18
SG11201701135WA (en) 2017-03-30
EP3185883A1 (en) 2017-07-05
RU2017110093A (ru) 2018-10-01
MX2017002476A (es) 2017-08-14
EP3185883A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CA2832910C (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10500249B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10562947B2 (en) Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US20150258192A1 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis
NZ616672B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123